Caprihans India（509486）株式概要カプリハンス・インディア社はインド国内外で医薬品パッケージング事業を展開している。 詳細509486 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6報酬当社が推定した公正価値より90.2%で取引されている リスク分析過去5年間で収益は年間44.6%減少しました。 意味のある時価総額がありません ( ₹1B )Indian市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る509486 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹76.8788.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-622m13b2016201920222025202620282031Revenue ₹13.1bEarnings ₹1.2bAdvancedSet Fair ValueView all narrativesCaprihans India Limited 競合他社Chemcrux EnterprisesSymbol: BSE:540395Market cap: ₹1.4bDeep PolymersSymbol: BSE:541778Market cap: ₹941.8mTirupati Starch and ChemicalsSymbol: BSE:524582Market cap: ₹1.2bVital ChemtechSymbol: NSEI:VITALMarket cap: ₹1.3b価格と性能株価の高値、安値、推移の概要Caprihans India過去の株価現在の株価₹76.8752週高値₹167.7052週安値₹50.30ベータ0.661ヶ月の変化-3.91%3ヶ月変化19.36%1年変化-43.00%3年間の変化-48.89%5年間の変化-52.40%IPOからの変化-55.16%最新ニュースReported Earnings • May 26Full year 2026 earnings released: ₹32.08 loss per share (vs ₹46.26 loss in FY 2025)Full year 2026 results: ₹32.08 loss per share (improved from ₹46.26 loss in FY 2025). Revenue: ₹7.43b (flat on FY 2025). Net loss: ₹470.0m (loss narrowed 24% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.Board Change • Apr 23High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Executive Independent Director Sanjeev Tole was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹986.3m market cap, or US$10.6m).New Risk • Mar 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹883.6m (US$9.57m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Market cap is less than US$10m (₹883.6m market cap, or US$9.57m).Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹10.67 loss per share (vs ₹14.13 loss in 3Q 2025)Third quarter 2026 results: ₹10.67 loss per share (improved from ₹14.13 loss in 3Q 2025). Revenue: ₹1.78b (down 5.0% from 3Q 2025). Net loss: ₹156.0m (loss narrowed 16% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 13Second quarter 2026 earnings released: ₹17.02 loss per share (vs ₹21.59 loss in 2Q 2025)Second quarter 2026 results: ₹17.02 loss per share (improved from ₹21.59 loss in 2Q 2025). Revenue: ₹1.79b (down 5.1% from 2Q 2025). Net loss: ₹248.9m (loss narrowed 12% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.最新情報をもっと見るRecent updatesReported Earnings • May 26Full year 2026 earnings released: ₹32.08 loss per share (vs ₹46.26 loss in FY 2025)Full year 2026 results: ₹32.08 loss per share (improved from ₹46.26 loss in FY 2025). Revenue: ₹7.43b (flat on FY 2025). Net loss: ₹470.0m (loss narrowed 24% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.Board Change • Apr 23High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Executive Independent Director Sanjeev Tole was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹986.3m market cap, or US$10.6m).New Risk • Mar 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹883.6m (US$9.57m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Market cap is less than US$10m (₹883.6m market cap, or US$9.57m).Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹10.67 loss per share (vs ₹14.13 loss in 3Q 2025)Third quarter 2026 results: ₹10.67 loss per share (improved from ₹14.13 loss in 3Q 2025). Revenue: ₹1.78b (down 5.0% from 3Q 2025). Net loss: ₹156.0m (loss narrowed 16% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 13Second quarter 2026 earnings released: ₹17.02 loss per share (vs ₹21.59 loss in 2Q 2025)Second quarter 2026 results: ₹17.02 loss per share (improved from ₹21.59 loss in 2Q 2025). Revenue: ₹1.79b (down 5.1% from 2Q 2025). Net loss: ₹248.9m (loss narrowed 12% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.お知らせ • Sep 01Caprihans India Limited, Annual General Meeting, Sep 23, 2025Caprihans India Limited, Annual General Meeting, Sep 23, 2025, at 12:00 Indian Standard Time.Reported Earnings • Aug 12First quarter 2026 earnings released: ₹9.27 loss per share (vs ₹13.41 loss in 1Q 2025)First quarter 2026 results: ₹9.27 loss per share (improved from ₹13.41 loss in 1Q 2025). Revenue: ₹1.85b (up 3.7% from 1Q 2025). Net loss: ₹135.6m (loss narrowed 23% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.お知らせ • Aug 04Caprihans India Limited to Report Q1, 2026 Results on Aug 11, 2025Caprihans India Limited announced that they will report Q1, 2026 results on Aug 11, 2025Reported Earnings • May 28Full year 2025 earnings released: ₹46.26 loss per share (vs ₹39.30 loss in FY 2024)Full year 2025 results: ₹46.26 loss per share (further deteriorated from ₹39.30 loss in FY 2024). Revenue: ₹7.68b (up 10% from FY 2024). Net loss: ₹621.8m (loss widened 21% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹2.12b market cap, or US$24.7m).Reported Earnings • Feb 12Third quarter 2025 earnings released: ₹14.13 loss per share (vs ₹10.39 loss in 3Q 2024)Third quarter 2025 results: ₹14.13 loss per share (further deteriorated from ₹10.39 loss in 3Q 2024). Revenue: ₹1.95b (up 21% from 3Q 2024). Net loss: ₹185.6m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.New Risk • Nov 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.9% operating cash flow to total debt). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹1.87b market cap, or US$22.1m).New Risk • Nov 12New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.9% operating cash flow to total debt). Earnings have declined by 14% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹2.16b market cap, or US$25.6m).お知らせ • Oct 15Caprihans India Limited announced that it expects to receive INR 240 million in funding from Bilcare Mauritius LimitedCaprihans India Limited announced a private placement of 4,800,000 for the gross proceeds of INR 50 per warrant for the gross proceeds of INR 240,000,000 on October 14, 2024. The warrants will be exercised at an exercise price of INR 150 per share. The warrants will be issued on preferential basis. The transaction will include participation from new investor, Bilcare Mauritius Limited. The transaction has been approved by the shareholders of the company.Board Change • Oct 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairperson, MD & President Ankita Kariya is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 27Caprihans India Limited Approves Appointment of Kavaseri R Viswanathan as A Non-Executive, Independent DirectorCaprihans India Limited approved Appointment of Mr. Kavaseri R Viswanathan as a Non-Executive, Independent Director of the Company for a term of five years effective from September 04, 2024 to September 03, 2029.お知らせ • Sep 25Caprihans India Limited Announces Cessation of Board of DirectorsCaprihans India Limited announced that Mr. Siddharth Shyam Shetye and Mr. Nitin Joshi, who served as an Independent Directors of the company from September 26, 2019 has concluded their tenure as an Independent Directors on the Board of the Company respectively. Their term officially ended from the close of business hours on September 25, 2024, following completion of their second term. Reason for change: Cessation of directorship due to completion of Second term as an Independent Director from the closing hours of September 25, 2024.お知らせ • Sep 06Caprihans India Limited, Annual General Meeting, Sep 26, 2024Caprihans India Limited, Annual General Meeting, Sep 26, 2024.お知らせ • Sep 04+ 2 more updatesCaprihans India Limited to Report Q2, 2025 Results on Nov 14, 2024Caprihans India Limited announced that they will report Q2, 2025 results on Nov 14, 2024Reported Earnings • Aug 13First quarter 2025 earnings released: ₹13.41 loss per share (vs ₹8.13 loss in 1Q 2024)First quarter 2025 results: ₹13.41 loss per share (further deteriorated from ₹8.13 loss in 1Q 2024). Revenue: ₹1.86b (up 10% from 1Q 2024). Net loss: ₹176.1m (loss widened 65% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.お知らせ • Aug 05Caprihans India Limited to Report Q1, 2025 Results on Aug 12, 2024Caprihans India Limited announced that they will report Q1, 2025 results on Aug 12, 2024Reported Earnings • May 28Full year 2024 earnings released: ₹39.31 loss per share (vs ₹54.64 profit in FY 2023)Full year 2024 results: ₹39.31 loss per share (down from ₹54.64 profit in FY 2023). Revenue: ₹7.22b (down 22% from FY 2023). Net loss: ₹516.2m (down 172% from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 11% per year.New Risk • Mar 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.6x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₹2.18b market cap, or US$26.0m).Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹144, the stock trades at a trailing P/E ratio of 3.1x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 69% over the past three years.Reported Earnings • Feb 11Third quarter 2024 earnings released: ₹10.39 loss per share (vs ₹0.71 loss in 3Q 2023)Third quarter 2024 results: ₹10.39 loss per share (further deteriorated from ₹0.71 loss in 3Q 2023). Revenue: ₹1.67b (up 100% from 3Q 2023). Net loss: ₹136.4m (loss widened ₹127.0m from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth.New Risk • Jan 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₹2.78b market cap, or US$33.4m).Valuation Update With 7 Day Price Move • Jan 18Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹235, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 173% over the past three years.お知らせ • Sep 09+ 3 more updatesCaprihans India Limited to Report Q2, 2024 Results on Nov 14, 2023Caprihans India Limited announced that they will report Q2, 2024 results on Nov 14, 2023Reported Earnings • Aug 12First quarter 2024 earnings released: ₹8.13 loss per share (vs ₹1.18 profit in 1Q 2023)First quarter 2024 results: ₹8.13 loss per share (down from ₹1.18 profit in 1Q 2023). Revenue: ₹1.76b (up 60% from 1Q 2023). Net loss: ₹106.7m (down ₹122.1m from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 04Caprihans India Limited to Report Q1, 2024 Results on Aug 11, 2023Caprihans India Limited announced that they will report Q1, 2024 results on Aug 11, 2023New Risk • Jul 27New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₹3.01b market cap, or US$36.7m).Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹227, the stock trades at a trailing P/E ratio of 26.7x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 368% over the past three years.Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹190, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 273% over the past three years.Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹164, the stock trades at a trailing P/E ratio of 19.3x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 222% over the past three years.Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹130, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 225% over the past three years.お知らせ • May 19Caprihans India Limited to Report Fiscal Year 2023 Results on May 26, 2023Caprihans India Limited announced that they will report fiscal year 2023 results on May 26, 2023Valuation Update With 7 Day Price Move • Mar 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹121, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 254% over the past three years.Reported Earnings • Feb 08Third quarter 2023 earnings released: ₹0.71 loss per share (vs ₹3.84 profit in 3Q 2022)Third quarter 2023 results: ₹0.71 loss per share (down from ₹3.84 profit in 3Q 2022). Revenue: ₹854.0m (down 14% from 3Q 2022). Net loss: ₹9.35m (down 119% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 02Caprihans India Limited to Report Q3, 2023 Results on Feb 07, 2023Caprihans India Limited announced that they will report Q3, 2023 results at 12:15 PM, Indian Standard Time on Feb 07, 2023お知らせ • Dec 29Caprihans India Limited Approves Executive ChangesThe board of directors of Caprihans India Limited at meeting held on December 28, 2022, approved the appointment of Mr. Sudhir Pendse as Non-Executive Independent Director (Additional Director) of the company to hold such office with effect from December 28, 2022 upto the date of the upcoming Annual/Extra Ordinary General Meeting of the Company. Mr. Pendse is a Commerce Graduate with Diploma in Exim Policies and Procedure . He also holds diploma in French language He has more than 30 years of experience in the field of Export Import, Exim logistics etc.; The company approved the resignation of Mr. Narendra Kumar Lodha as Non- Executive Non Independent Director with effect immediate effect., resignation of Mr. Chandrashekhar Joglekar as Non- Executive Non Independent Director of the Company with immediate effect.; resignation of Mr. Tanuj Kumar Lodha as Non- Executive Independent Director of the Company with immediate effect due to prior engagement and continuous travel.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹138, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 212% over the past three years.Reported Earnings • Nov 10Second quarter 2023 earnings released: EPS: ₹4.35 (vs ₹1.43 in 2Q 2022)Second quarter 2023 results: EPS: ₹4.35 (up from ₹1.43 in 2Q 2022). Revenue: ₹935.8m (flat on 2Q 2022). Net income: ₹57.2m (up 204% from 2Q 2022). Profit margin: 6.1% (up from 2.0% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 49% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹163, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 263% over the past three years.お知らせ • Oct 30Caprihans India Limited to Report Q2, 2023 Results on Nov 05, 2022Caprihans India Limited announced that they will report Q2, 2023 results at 12:15 PM, Indian Standard Time on Nov 05, 2022お知らせ • Oct 20Caprihans India Limited Announces Change in DirectorateCaprihans India Limited announced Resignation of Mr. Robin Banerjee, Managing Director: Mr. Robin Banerjee has resigned from position of the Managing Director of the Company vide his letter dated October 18, 2022 with effect from October 19, 2022. Mr. Shreyans Mohan Bhandari is appointed as Non-Executive Non-Independent Director of the Company to hold such office with effect from October 19, 2022 upto the date of the ensuing Annual/Extra Ordinary General Meeting of the Company.Board Change • Oct 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Additional Non- Executive Independent Director Tanuj Lodha was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 11Caprihans India Limited Appoints Tanuj Lodha as A Non- Executive IndependentCaprihans India Limited appointed Tanuj Lodha as a Non- Executive Independent for period of 5 years with effect from May 03, 2022 upto May 02, 2027 at its AGM held on August 10, 2022. Mr. Tanuj Lodha aged 42, is an Advocate by profession and is a Senior Partner at Lodha & Lodha Advocates. Mr. Lodha is a Bachelor of Law (LLB), Chartered Accountant, MBA finance & marketing from the Indian School of Business. Mr. Lodha specializes in commercial laws including Arbitration, IBC, Real Estate & Company Laws. Mr. Lodha has represented several Corporates and other Persons in important matters and has appeared in several reported judgements' 'Mr. Lodha is an avid Golfer and actively participates in charitable causes.お知らせ • Jul 28Caprihans India Limited to Report Q1, 2023 Results on Aug 05, 2022Caprihans India Limited announced that they will report Q1, 2023 results on Aug 05, 2022Reported Earnings • Jul 20Full year 2022 earnings released: EPS: ₹12.79 (vs ₹15.40 in FY 2021)Full year 2022 results: EPS: ₹12.79 (down from ₹15.40 in FY 2021). Revenue: ₹3.93b (up 33% from FY 2021). Net income: ₹167.9m (down 17% from FY 2021). Profit margin: 4.3% (down from 6.8% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 51% per year whereas the company’s share price has increased by 56% per year.お知らせ • Jul 19Caprihans India Limited, Annual General Meeting, Aug 10, 2022Caprihans India Limited, Annual General Meeting, Aug 10, 2022, at 11:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2022; to appoint a Director in place of Mr. Chandrashekhar Joglekar (DIN: 07265143); to appoint Mr. Tanuj Kumar Lodha (DIN: 06874388) as a Non-Executive, Independent Director of the Company; to ratify remuneration of Cost Auditors; and to reappoint Mr. Robin Banerjee (DIN 00008893) as Managing Director and payment of remuneration.Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹132, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 148% over the past three years.Reported Earnings • May 15Full year 2022 earnings released: EPS: ₹12.79 (vs ₹15.40 in FY 2021)Full year 2022 results: EPS: ₹12.79 (down from ₹15.40 in FY 2021). Revenue: ₹3.97b (up 35% from FY 2021). Net income: ₹167.9m (down 17% from FY 2021). Profit margin: 4.2% (down from 6.8% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.お知らせ • May 07Caprihans India Limited to Report Fiscal Year 2022 Results on May 12, 2022Caprihans India Limited announced that they will report fiscal year 2022 results on May 12, 2022Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Non-Executive & Non-Independent Director Chandrashekhar Joglekar was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹136, the stock trades at a trailing P/E ratio of 9.2x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 132% over the past three years.お知らせ • Mar 30Caprihans India Limited Announces Resignation of Anjali Seth as Independent DirectorCaprihans India Limited announced that Ms. Anjali Seth (DIN: 05234352), Independent Director, vide letter dated March 29, 2022, has tendered her resignation from the Board of the Company.Reported Earnings • Feb 11Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹3.84 (down from ₹4.31 in 3Q 2021). Revenue: ₹1.00b (up 38% from 3Q 2021). Net income: ₹50.4m (down 11% from 3Q 2021). Profit margin: 5.0% (down from 7.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 03Caprihans India Limited to Report Q3, 2022 Results on Feb 10, 2022Caprihans India Limited announced that they will report Q3, 2022 results on Feb 10, 2022Board Change • Jan 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Non-Executive & Non-Independent Director Chandrashekhar Joglekar was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹138, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 102% over the past three years.Reported Earnings • Nov 11Second quarter 2022 earnings released: EPS ₹1.43 (vs ₹3.71 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹943.3m (up 23% from 2Q 2021). Net income: ₹18.8m (down 61% from 2Q 2021). Profit margin: 2.0% (down from 6.3% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹151, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 95% over the past three years.Reported Earnings • Aug 09First quarter 2022 earnings released: EPS ₹3.83 (vs ₹1.77 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹851.6m (up 49% from 1Q 2021). Net income: ₹50.3m (up 117% from 1Q 2021). Profit margin: 5.9% (up from 4.1% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.Reported Earnings • Jun 27Full year 2021 earnings released: EPS ₹15.40 (vs ₹7.00 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.04b (up 5.6% from FY 2020). Net income: ₹202.2m (up 120% from FY 2020). Profit margin: 6.6% (up from 3.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹132, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 69% over the past three years.Valuation Update With 7 Day Price Move • May 11Investor sentiment improved over the past weekAfter last week's 37% share price gain to ₹130, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 56% over the past three years.Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹93.00, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 8.1% over the past three years.お知らせ • Feb 04Caprihans India Limited to Report Q3, 2021 Results on Feb 10, 2021Caprihans India Limited announced that they will report Q3, 2021 results on Feb 10, 2021お知らせ • Jan 22Caprihans India Limited Announces Sad Demise of K.V. Mani, Independent Director of the CompanyCaprihans India Limited announced the sad demise of Mr. K.V. Mani (DIN: 00533148), Independent Director of the Company on the night of January 20, 2021.Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹87.30, the stock is trading at a trailing P/E ratio of 8.4x, up from the previous P/E ratio of 7x. This compares to an average P/E of 18x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 23%.Is New 90 Day High Low • Dec 28New 90-day high: ₹84.40The company is up 56% from its price of ₹54.15 on 29 September 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period.Is New 90 Day High Low • Dec 08New 90-day high: ₹81.15The company is up 51% from its price of ₹53.75 on 09 September 2020. The Indian market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period.Valuation Update With 7 Day Price Move • Nov 23Market bids up stock over the past weekAfter last week's 16% share price gain to ₹76.15, the stock is trading at a trailing P/E ratio of 7.3x, up from the previous P/E ratio of 6.3x. This compares to an average P/E of 16x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 32%.Valuation Update With 7 Day Price Move • Nov 17Market bids up stock over the past weekAfter last week's 18% share price gain to ₹75.45, the stock is trading at a trailing P/E ratio of 7.3x, up from the previous P/E ratio of 6.2x. This compares to an average P/E of 16x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 32%.Reported Earnings • Nov 11Second quarter 2021 earnings released: EPS ₹3.71The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹819.3m (up 5.8% from 2Q 2020). Net income: ₹48.7m (up 205% from 2Q 2020). Profit margin: 5.9% (up from 2.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 09New 90-day high: ₹66.80The company is up 27% from its price of ₹52.50 on 11 August 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period.お知らせ • Sep 09+ 1 more updateCaprihans India Limited Announces Not to Recommend Any Dividend for Financial Year 2019-20Caprihans India Limited announced that in order to conserve financial resources owing to ongoing COVID-19 pandemic, the Board has not recommended any dividend for financial year 2019-20.お知らせ • Aug 09Caprihans India Limited to Report Q1, 2021 Results on Aug 12, 2020Caprihans India Limited announced that they will report Q1, 2021 results on Aug 12, 2020お知らせ • Jun 17Caprihans India Limited to Report Fiscal Year 2020 Results on Jun 19, 2020Caprihans India Limited announced that they will report fiscal year 2020 results on Jun 19, 2020株主還元509486IN ChemicalsIN 市場7D-4.5%0.3%-0.7%1Y-43.0%-5.5%-4.3%株主還元を見る業界別リターン: 509486過去 1 年間で-5.5 % の収益を上げたIndian Chemicals業界を下回りました。リターン対市場: 509486は、過去 1 年間で-4.3 % のリターンを上げたIndian市場を下回りました。価格変動Is 509486's price volatile compared to industry and market?509486 volatility509486 Average Weekly Movement9.3%Chemicals Industry Average Movement7.3%Market Average Movement7.2%10% most volatile stocks in IN Market10.2%10% least volatile stocks in IN Market4.7%安定した株価: 509486の株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 509486の weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてIndianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1946540Ankita Kariyacaprihansindia.comCaprihans India Limited はインド国内外で医薬品パッケージング事業を展開。硬質・軟質ポリ塩化ビニル（PVC）フィルム、ポリ塩化ビニリデン（PVDC）コーティングフィルム、プラスチック押出製品、アルミ箔、その他製品を提供。また、Duplex、Triplex、Ultra、Ultra Tx、Armour、Aclar、Excel、Exxtra、Optra、BAPPの名称でブリスターフィルム、Venus、Venus PR、Venus SBC、Tropical Foil、Nutra Venus、Vento Venusの名称でブリスターホイルも提供している；リディングホイルはZeon、Zeon+、Zenith、Zeon+PR、Suppo Zenith、Zeon PRの名称で、CrホイルはCrispak AP-PT、Crispak PP、Crispak PL、Crispak PTの名称で、ラミネートはLamiflexの名称で提供している。また、製剤安定性試験、ブリスター／フォイル設計・開発、医薬品ブランド革新、分析研究・市場調査、包装試験・監査サービスなどの医薬品包装研究サービスも提供している。製品の輸出も行っている。1946年に設立され、インドのプネーに本社を置く。Caprihans India Limited は Bilcare Mauritius Limited の子会社である。もっと見るCaprihans India Limited 基礎のまとめCaprihans India の収益と売上を時価総額と比較するとどうか。509486 基礎統計学時価総額₹1.27b収益（TTM）-₹470.00m売上高(TTM)₹7.02b0.2xP/Sレシオ-2.6xPER（株価収益率509486 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計509486 損益計算書（TTM）収益₹7.02b売上原価₹4.81b売上総利益₹2.21bその他の費用₹2.68b収益-₹470.00m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-29.53グロス・マージン31.45%純利益率-6.70%有利子負債／自己資本比率154.7%509486 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 11:33終値2026/06/10 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Caprihans India Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Naveed MD.FirstCall Research
Reported Earnings • May 26Full year 2026 earnings released: ₹32.08 loss per share (vs ₹46.26 loss in FY 2025)Full year 2026 results: ₹32.08 loss per share (improved from ₹46.26 loss in FY 2025). Revenue: ₹7.43b (flat on FY 2025). Net loss: ₹470.0m (loss narrowed 24% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.
Board Change • Apr 23High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Executive Independent Director Sanjeev Tole was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹986.3m market cap, or US$10.6m).
New Risk • Mar 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹883.6m (US$9.57m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Market cap is less than US$10m (₹883.6m market cap, or US$9.57m).
Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹10.67 loss per share (vs ₹14.13 loss in 3Q 2025)Third quarter 2026 results: ₹10.67 loss per share (improved from ₹14.13 loss in 3Q 2025). Revenue: ₹1.78b (down 5.0% from 3Q 2025). Net loss: ₹156.0m (loss narrowed 16% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 13Second quarter 2026 earnings released: ₹17.02 loss per share (vs ₹21.59 loss in 2Q 2025)Second quarter 2026 results: ₹17.02 loss per share (improved from ₹21.59 loss in 2Q 2025). Revenue: ₹1.79b (down 5.1% from 2Q 2025). Net loss: ₹248.9m (loss narrowed 12% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 26Full year 2026 earnings released: ₹32.08 loss per share (vs ₹46.26 loss in FY 2025)Full year 2026 results: ₹32.08 loss per share (improved from ₹46.26 loss in FY 2025). Revenue: ₹7.43b (flat on FY 2025). Net loss: ₹470.0m (loss narrowed 24% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.
Board Change • Apr 23High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Executive Independent Director Sanjeev Tole was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹986.3m market cap, or US$10.6m).
New Risk • Mar 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹883.6m (US$9.57m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Market cap is less than US$10m (₹883.6m market cap, or US$9.57m).
Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹10.67 loss per share (vs ₹14.13 loss in 3Q 2025)Third quarter 2026 results: ₹10.67 loss per share (improved from ₹14.13 loss in 3Q 2025). Revenue: ₹1.78b (down 5.0% from 3Q 2025). Net loss: ₹156.0m (loss narrowed 16% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 13Second quarter 2026 earnings released: ₹17.02 loss per share (vs ₹21.59 loss in 2Q 2025)Second quarter 2026 results: ₹17.02 loss per share (improved from ₹21.59 loss in 2Q 2025). Revenue: ₹1.79b (down 5.1% from 2Q 2025). Net loss: ₹248.9m (loss narrowed 12% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.
お知らせ • Sep 01Caprihans India Limited, Annual General Meeting, Sep 23, 2025Caprihans India Limited, Annual General Meeting, Sep 23, 2025, at 12:00 Indian Standard Time.
Reported Earnings • Aug 12First quarter 2026 earnings released: ₹9.27 loss per share (vs ₹13.41 loss in 1Q 2025)First quarter 2026 results: ₹9.27 loss per share (improved from ₹13.41 loss in 1Q 2025). Revenue: ₹1.85b (up 3.7% from 1Q 2025). Net loss: ₹135.6m (loss narrowed 23% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 04Caprihans India Limited to Report Q1, 2026 Results on Aug 11, 2025Caprihans India Limited announced that they will report Q1, 2026 results on Aug 11, 2025
Reported Earnings • May 28Full year 2025 earnings released: ₹46.26 loss per share (vs ₹39.30 loss in FY 2024)Full year 2025 results: ₹46.26 loss per share (further deteriorated from ₹39.30 loss in FY 2024). Revenue: ₹7.68b (up 10% from FY 2024). Net loss: ₹621.8m (loss widened 21% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹2.12b market cap, or US$24.7m).
Reported Earnings • Feb 12Third quarter 2025 earnings released: ₹14.13 loss per share (vs ₹10.39 loss in 3Q 2024)Third quarter 2025 results: ₹14.13 loss per share (further deteriorated from ₹10.39 loss in 3Q 2024). Revenue: ₹1.95b (up 21% from 3Q 2024). Net loss: ₹185.6m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
New Risk • Nov 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.9% operating cash flow to total debt). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹1.87b market cap, or US$22.1m).
New Risk • Nov 12New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.9% operating cash flow to total debt). Earnings have declined by 14% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹2.16b market cap, or US$25.6m).
お知らせ • Oct 15Caprihans India Limited announced that it expects to receive INR 240 million in funding from Bilcare Mauritius LimitedCaprihans India Limited announced a private placement of 4,800,000 for the gross proceeds of INR 50 per warrant for the gross proceeds of INR 240,000,000 on October 14, 2024. The warrants will be exercised at an exercise price of INR 150 per share. The warrants will be issued on preferential basis. The transaction will include participation from new investor, Bilcare Mauritius Limited. The transaction has been approved by the shareholders of the company.
Board Change • Oct 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairperson, MD & President Ankita Kariya is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 27Caprihans India Limited Approves Appointment of Kavaseri R Viswanathan as A Non-Executive, Independent DirectorCaprihans India Limited approved Appointment of Mr. Kavaseri R Viswanathan as a Non-Executive, Independent Director of the Company for a term of five years effective from September 04, 2024 to September 03, 2029.
お知らせ • Sep 25Caprihans India Limited Announces Cessation of Board of DirectorsCaprihans India Limited announced that Mr. Siddharth Shyam Shetye and Mr. Nitin Joshi, who served as an Independent Directors of the company from September 26, 2019 has concluded their tenure as an Independent Directors on the Board of the Company respectively. Their term officially ended from the close of business hours on September 25, 2024, following completion of their second term. Reason for change: Cessation of directorship due to completion of Second term as an Independent Director from the closing hours of September 25, 2024.
お知らせ • Sep 06Caprihans India Limited, Annual General Meeting, Sep 26, 2024Caprihans India Limited, Annual General Meeting, Sep 26, 2024.
お知らせ • Sep 04+ 2 more updatesCaprihans India Limited to Report Q2, 2025 Results on Nov 14, 2024Caprihans India Limited announced that they will report Q2, 2025 results on Nov 14, 2024
Reported Earnings • Aug 13First quarter 2025 earnings released: ₹13.41 loss per share (vs ₹8.13 loss in 1Q 2024)First quarter 2025 results: ₹13.41 loss per share (further deteriorated from ₹8.13 loss in 1Q 2024). Revenue: ₹1.86b (up 10% from 1Q 2024). Net loss: ₹176.1m (loss widened 65% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
お知らせ • Aug 05Caprihans India Limited to Report Q1, 2025 Results on Aug 12, 2024Caprihans India Limited announced that they will report Q1, 2025 results on Aug 12, 2024
Reported Earnings • May 28Full year 2024 earnings released: ₹39.31 loss per share (vs ₹54.64 profit in FY 2023)Full year 2024 results: ₹39.31 loss per share (down from ₹54.64 profit in FY 2023). Revenue: ₹7.22b (down 22% from FY 2023). Net loss: ₹516.2m (down 172% from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 11% per year.
New Risk • Mar 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.6x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₹2.18b market cap, or US$26.0m).
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹144, the stock trades at a trailing P/E ratio of 3.1x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 69% over the past three years.
Reported Earnings • Feb 11Third quarter 2024 earnings released: ₹10.39 loss per share (vs ₹0.71 loss in 3Q 2023)Third quarter 2024 results: ₹10.39 loss per share (further deteriorated from ₹0.71 loss in 3Q 2023). Revenue: ₹1.67b (up 100% from 3Q 2023). Net loss: ₹136.4m (loss widened ₹127.0m from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth.
New Risk • Jan 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (₹2.78b market cap, or US$33.4m).
Valuation Update With 7 Day Price Move • Jan 18Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹235, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 173% over the past three years.
お知らせ • Sep 09+ 3 more updatesCaprihans India Limited to Report Q2, 2024 Results on Nov 14, 2023Caprihans India Limited announced that they will report Q2, 2024 results on Nov 14, 2023
Reported Earnings • Aug 12First quarter 2024 earnings released: ₹8.13 loss per share (vs ₹1.18 profit in 1Q 2023)First quarter 2024 results: ₹8.13 loss per share (down from ₹1.18 profit in 1Q 2023). Revenue: ₹1.76b (up 60% from 1Q 2023). Net loss: ₹106.7m (down ₹122.1m from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 04Caprihans India Limited to Report Q1, 2024 Results on Aug 11, 2023Caprihans India Limited announced that they will report Q1, 2024 results on Aug 11, 2023
New Risk • Jul 27New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₹3.01b market cap, or US$36.7m).
Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹227, the stock trades at a trailing P/E ratio of 26.7x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 368% over the past three years.
Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹190, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 273% over the past three years.
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹164, the stock trades at a trailing P/E ratio of 19.3x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 222% over the past three years.
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹130, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 225% over the past three years.
お知らせ • May 19Caprihans India Limited to Report Fiscal Year 2023 Results on May 26, 2023Caprihans India Limited announced that they will report fiscal year 2023 results on May 26, 2023
Valuation Update With 7 Day Price Move • Mar 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹121, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 254% over the past three years.
Reported Earnings • Feb 08Third quarter 2023 earnings released: ₹0.71 loss per share (vs ₹3.84 profit in 3Q 2022)Third quarter 2023 results: ₹0.71 loss per share (down from ₹3.84 profit in 3Q 2022). Revenue: ₹854.0m (down 14% from 3Q 2022). Net loss: ₹9.35m (down 119% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 02Caprihans India Limited to Report Q3, 2023 Results on Feb 07, 2023Caprihans India Limited announced that they will report Q3, 2023 results at 12:15 PM, Indian Standard Time on Feb 07, 2023
お知らせ • Dec 29Caprihans India Limited Approves Executive ChangesThe board of directors of Caprihans India Limited at meeting held on December 28, 2022, approved the appointment of Mr. Sudhir Pendse as Non-Executive Independent Director (Additional Director) of the company to hold such office with effect from December 28, 2022 upto the date of the upcoming Annual/Extra Ordinary General Meeting of the Company. Mr. Pendse is a Commerce Graduate with Diploma in Exim Policies and Procedure . He also holds diploma in French language He has more than 30 years of experience in the field of Export Import, Exim logistics etc.; The company approved the resignation of Mr. Narendra Kumar Lodha as Non- Executive Non Independent Director with effect immediate effect., resignation of Mr. Chandrashekhar Joglekar as Non- Executive Non Independent Director of the Company with immediate effect.; resignation of Mr. Tanuj Kumar Lodha as Non- Executive Independent Director of the Company with immediate effect due to prior engagement and continuous travel.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹138, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 212% over the past three years.
Reported Earnings • Nov 10Second quarter 2023 earnings released: EPS: ₹4.35 (vs ₹1.43 in 2Q 2022)Second quarter 2023 results: EPS: ₹4.35 (up from ₹1.43 in 2Q 2022). Revenue: ₹935.8m (flat on 2Q 2022). Net income: ₹57.2m (up 204% from 2Q 2022). Profit margin: 6.1% (up from 2.0% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 49% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₹163, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 263% over the past three years.
お知らせ • Oct 30Caprihans India Limited to Report Q2, 2023 Results on Nov 05, 2022Caprihans India Limited announced that they will report Q2, 2023 results at 12:15 PM, Indian Standard Time on Nov 05, 2022
お知らせ • Oct 20Caprihans India Limited Announces Change in DirectorateCaprihans India Limited announced Resignation of Mr. Robin Banerjee, Managing Director: Mr. Robin Banerjee has resigned from position of the Managing Director of the Company vide his letter dated October 18, 2022 with effect from October 19, 2022. Mr. Shreyans Mohan Bhandari is appointed as Non-Executive Non-Independent Director of the Company to hold such office with effect from October 19, 2022 upto the date of the ensuing Annual/Extra Ordinary General Meeting of the Company.
Board Change • Oct 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Additional Non- Executive Independent Director Tanuj Lodha was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 11Caprihans India Limited Appoints Tanuj Lodha as A Non- Executive IndependentCaprihans India Limited appointed Tanuj Lodha as a Non- Executive Independent for period of 5 years with effect from May 03, 2022 upto May 02, 2027 at its AGM held on August 10, 2022. Mr. Tanuj Lodha aged 42, is an Advocate by profession and is a Senior Partner at Lodha & Lodha Advocates. Mr. Lodha is a Bachelor of Law (LLB), Chartered Accountant, MBA finance & marketing from the Indian School of Business. Mr. Lodha specializes in commercial laws including Arbitration, IBC, Real Estate & Company Laws. Mr. Lodha has represented several Corporates and other Persons in important matters and has appeared in several reported judgements' 'Mr. Lodha is an avid Golfer and actively participates in charitable causes.
お知らせ • Jul 28Caprihans India Limited to Report Q1, 2023 Results on Aug 05, 2022Caprihans India Limited announced that they will report Q1, 2023 results on Aug 05, 2022
Reported Earnings • Jul 20Full year 2022 earnings released: EPS: ₹12.79 (vs ₹15.40 in FY 2021)Full year 2022 results: EPS: ₹12.79 (down from ₹15.40 in FY 2021). Revenue: ₹3.93b (up 33% from FY 2021). Net income: ₹167.9m (down 17% from FY 2021). Profit margin: 4.3% (down from 6.8% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 51% per year whereas the company’s share price has increased by 56% per year.
お知らせ • Jul 19Caprihans India Limited, Annual General Meeting, Aug 10, 2022Caprihans India Limited, Annual General Meeting, Aug 10, 2022, at 11:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2022; to appoint a Director in place of Mr. Chandrashekhar Joglekar (DIN: 07265143); to appoint Mr. Tanuj Kumar Lodha (DIN: 06874388) as a Non-Executive, Independent Director of the Company; to ratify remuneration of Cost Auditors; and to reappoint Mr. Robin Banerjee (DIN 00008893) as Managing Director and payment of remuneration.
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹132, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 148% over the past three years.
Reported Earnings • May 15Full year 2022 earnings released: EPS: ₹12.79 (vs ₹15.40 in FY 2021)Full year 2022 results: EPS: ₹12.79 (down from ₹15.40 in FY 2021). Revenue: ₹3.97b (up 35% from FY 2021). Net income: ₹167.9m (down 17% from FY 2021). Profit margin: 4.2% (down from 6.8% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
お知らせ • May 07Caprihans India Limited to Report Fiscal Year 2022 Results on May 12, 2022Caprihans India Limited announced that they will report fiscal year 2022 results on May 12, 2022
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Non-Executive & Non-Independent Director Chandrashekhar Joglekar was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹136, the stock trades at a trailing P/E ratio of 9.2x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 132% over the past three years.
お知らせ • Mar 30Caprihans India Limited Announces Resignation of Anjali Seth as Independent DirectorCaprihans India Limited announced that Ms. Anjali Seth (DIN: 05234352), Independent Director, vide letter dated March 29, 2022, has tendered her resignation from the Board of the Company.
Reported Earnings • Feb 11Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹3.84 (down from ₹4.31 in 3Q 2021). Revenue: ₹1.00b (up 38% from 3Q 2021). Net income: ₹50.4m (down 11% from 3Q 2021). Profit margin: 5.0% (down from 7.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 03Caprihans India Limited to Report Q3, 2022 Results on Feb 10, 2022Caprihans India Limited announced that they will report Q3, 2022 results on Feb 10, 2022
Board Change • Jan 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Non-Executive & Non-Independent Director Chandrashekhar Joglekar was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹138, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 102% over the past three years.
Reported Earnings • Nov 11Second quarter 2022 earnings released: EPS ₹1.43 (vs ₹3.71 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹943.3m (up 23% from 2Q 2021). Net income: ₹18.8m (down 61% from 2Q 2021). Profit margin: 2.0% (down from 6.3% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹151, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 95% over the past three years.
Reported Earnings • Aug 09First quarter 2022 earnings released: EPS ₹3.83 (vs ₹1.77 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹851.6m (up 49% from 1Q 2021). Net income: ₹50.3m (up 117% from 1Q 2021). Profit margin: 5.9% (up from 4.1% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Jun 27Full year 2021 earnings released: EPS ₹15.40 (vs ₹7.00 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.04b (up 5.6% from FY 2020). Net income: ₹202.2m (up 120% from FY 2020). Profit margin: 6.6% (up from 3.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹132, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 69% over the past three years.
Valuation Update With 7 Day Price Move • May 11Investor sentiment improved over the past weekAfter last week's 37% share price gain to ₹130, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 56% over the past three years.
Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹93.00, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 8.1% over the past three years.
お知らせ • Feb 04Caprihans India Limited to Report Q3, 2021 Results on Feb 10, 2021Caprihans India Limited announced that they will report Q3, 2021 results on Feb 10, 2021
お知らせ • Jan 22Caprihans India Limited Announces Sad Demise of K.V. Mani, Independent Director of the CompanyCaprihans India Limited announced the sad demise of Mr. K.V. Mani (DIN: 00533148), Independent Director of the Company on the night of January 20, 2021.
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹87.30, the stock is trading at a trailing P/E ratio of 8.4x, up from the previous P/E ratio of 7x. This compares to an average P/E of 18x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 23%.
Is New 90 Day High Low • Dec 28New 90-day high: ₹84.40The company is up 56% from its price of ₹54.15 on 29 September 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period.
Is New 90 Day High Low • Dec 08New 90-day high: ₹81.15The company is up 51% from its price of ₹53.75 on 09 September 2020. The Indian market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period.
Valuation Update With 7 Day Price Move • Nov 23Market bids up stock over the past weekAfter last week's 16% share price gain to ₹76.15, the stock is trading at a trailing P/E ratio of 7.3x, up from the previous P/E ratio of 6.3x. This compares to an average P/E of 16x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 32%.
Valuation Update With 7 Day Price Move • Nov 17Market bids up stock over the past weekAfter last week's 18% share price gain to ₹75.45, the stock is trading at a trailing P/E ratio of 7.3x, up from the previous P/E ratio of 6.2x. This compares to an average P/E of 16x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 32%.
Reported Earnings • Nov 11Second quarter 2021 earnings released: EPS ₹3.71The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹819.3m (up 5.8% from 2Q 2020). Net income: ₹48.7m (up 205% from 2Q 2020). Profit margin: 5.9% (up from 2.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 09New 90-day high: ₹66.80The company is up 27% from its price of ₹52.50 on 11 August 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period.
お知らせ • Sep 09+ 1 more updateCaprihans India Limited Announces Not to Recommend Any Dividend for Financial Year 2019-20Caprihans India Limited announced that in order to conserve financial resources owing to ongoing COVID-19 pandemic, the Board has not recommended any dividend for financial year 2019-20.
お知らせ • Aug 09Caprihans India Limited to Report Q1, 2021 Results on Aug 12, 2020Caprihans India Limited announced that they will report Q1, 2021 results on Aug 12, 2020
お知らせ • Jun 17Caprihans India Limited to Report Fiscal Year 2020 Results on Jun 19, 2020Caprihans India Limited announced that they will report fiscal year 2020 results on Jun 19, 2020
